Wuhan Hiteck Biological Pharma Co.,Ltd announced that it has received CNY 294.999985 million in funding from Nuode Asset Management Co., Ltd., Caitong Fund Management Co., Ltd., Shanghai Boshen Investment Center (Limited Partnership), Shenzhen Qianhai Eagle Fund Management Co., Ltd., UBS Group AG, Guodu Venture Capital Co., Ltd., and other investors
February 01, 2023
Share
On February 2, 2023, Wuhan Hiteck Biological Pharma Co.,Ltd closed the transaction. The company has raised gross proceeds of CNY 294,999,984.56, and paid underwriting sponsorship fees, audit and capital verification fees, legal fees and other issuance expenses of totaling CNY 6,392,924.53, and received net proceeds of CNY 288,607,060.03 in the transaction, of which CNY 8,790,226.00 was included in share capital, and CNY 279,816,834.03 was included in capital reserve-share premium.
Wuhan Hiteck Biological Pharma Co Ltd is a biopharmaceutical company. The Company operates five segments. The Biopharmaceutical segment is engaged in research, development, production and sales of biological products, and its primary product is mouse nerve growth factor for injection named Jinlujie. The Medical Technology Service segment is mainly involved in the technical development, technical consultation and technology transfer of chemical drugs. The In Vitro Diagnostic Reagents segment operates the research, development, production and sales of in vitro diagnostic reagents. The Pharmaceutical Sales and Wholesale segment is engaged in the sales and wholesale of pharmaceuticals. The Other segmentâs businesses include the cultivation and sales of Chinese herbal medicines, and the wholesale and retail of health products.
Wuhan Hiteck Biological Pharma Co.,Ltd announced that it has received CNY 294.999985 million in funding from Nuode Asset Management Co., Ltd., Caitong Fund Management Co., Ltd., Shanghai Boshen Investment Center (Limited Partnership), Shenzhen Qianhai Eagle Fund Management Co., Ltd., UBS Group AG, Guodu Venture Capital Co., Ltd., and other investors
WUHAN HITECK BIOLOGICAL PHARMA CO.,LTD 
